JP2006520377A5 - - Google Patents

Download PDF

Info

Publication number
JP2006520377A5
JP2006520377A5 JP2006506335A JP2006506335A JP2006520377A5 JP 2006520377 A5 JP2006520377 A5 JP 2006520377A5 JP 2006506335 A JP2006506335 A JP 2006506335A JP 2006506335 A JP2006506335 A JP 2006506335A JP 2006520377 A5 JP2006520377 A5 JP 2006520377A5
Authority
JP
Japan
Prior art keywords
weeks
testosterone
esters
undecanoate
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006506335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520377A (ja
JP4680891B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/000716 external-priority patent/WO2004080383A2/en
Publication of JP2006520377A publication Critical patent/JP2006520377A/ja
Publication of JP2006520377A5 publication Critical patent/JP2006520377A5/ja
Application granted granted Critical
Publication of JP4680891B2 publication Critical patent/JP4680891B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006506335A 2003-03-14 2004-03-15 許容可能な血清中テストステロン・レベルを信頼性高く達成するための方法及び医薬組成物 Expired - Lifetime JP4680891B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
PCT/IB2004/000716 WO2004080383A2 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (3)

Publication Number Publication Date
JP2006520377A JP2006520377A (ja) 2006-09-07
JP2006520377A5 true JP2006520377A5 (enExample) 2007-04-05
JP4680891B2 JP4680891B2 (ja) 2011-05-11

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506335A Expired - Lifetime JP4680891B2 (ja) 2003-03-14 2004-03-15 許容可能な血清中テストステロン・レベルを信頼性高く達成するための方法及び医薬組成物

Country Status (39)

Country Link
US (2) US7718640B2 (enExample)
EP (2) EP1457208B9 (enExample)
JP (1) JP4680891B2 (enExample)
KR (2) KR20080096717A (enExample)
CN (2) CN1761469B (enExample)
AR (1) AR043603A1 (enExample)
AT (1) ATE336251T1 (enExample)
AU (1) AU2004218893B2 (enExample)
BR (2) BRPI0400214A8 (enExample)
CA (1) CA2518910C (enExample)
CL (1) CL2004000527A1 (enExample)
CO (1) CO5700724A2 (enExample)
CR (1) CR7999A (enExample)
CY (1) CY1105794T1 (enExample)
DE (1) DE602004001893T2 (enExample)
DK (1) DK1457208T3 (enExample)
EA (1) EA011568B1 (enExample)
EC (1) ECSP056095A (enExample)
ES (1) ES2271772T3 (enExample)
HR (1) HRP20050781B1 (enExample)
IL (1) IL170473A (enExample)
IS (1) IS2565B (enExample)
JO (1) JO2505B1 (enExample)
ME (2) MEP14508A (enExample)
MX (1) MXPA04002395A (enExample)
NO (1) NO335179B1 (enExample)
NZ (1) NZ542321A (enExample)
PE (1) PE20041065A1 (enExample)
PL (1) PL1457208T3 (enExample)
PT (1) PT1457208E (enExample)
RS (1) RS51537B (enExample)
RU (2) RU2354381C2 (enExample)
SA (1) SA04250040B1 (enExample)
SI (1) SI1457208T1 (enExample)
TW (1) TWI345976B (enExample)
UA (1) UA82510C2 (enExample)
UY (1) UY28231A1 (enExample)
WO (1) WO2004080383A2 (enExample)
ZA (2) ZA200508313B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RU2623206C2 (ru) * 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
AU2013203784A1 (en) * 2012-04-06 2013-10-24 Kaushik J. Dave Needle assisted jet injection administration of testosterone compositions
SG11201407349UA (en) * 2012-05-09 2014-12-30 Univ Western Health Sciences Proliposomal testosterone formulations
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
EP2953667B1 (en) 2013-02-11 2019-10-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EP3131532A1 (de) 2014-04-16 2017-02-22 Veyx-Pharma GmbH Veterinärpharmazeutische zusammensetzung und deren verwendung
US20170246187A1 (en) * 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
MX2021007032A (es) * 2018-12-14 2021-10-22 Acerus Biopharma Inc Derivados activos de éster de testosterona, composiciones y usos de los mismos.
US12083130B2 (en) * 2019-10-03 2024-09-10 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
EP4164743A2 (en) * 2020-06-11 2023-04-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
HRP20000366B1 (en) * 1997-12-03 2009-08-31 Merck & Co. Inc. Long acting injectable formulations containing hydrogenated castor oil
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
AU756739B2 (en) 1998-06-19 2003-01-23 N.V. Organon Testosterone derivative
MXPA01009919A (es) 1999-04-01 2002-04-24 Akzo Nobel Nv Formulacion comprendiendo undecanoato de testosterona y aceite de ricino.
HK1049442B (en) * 2000-02-15 2007-06-15 Bayer Schering Pharma Aktiengesellschaft Male contraceptive formulation comprising norethisterone and testosterone undecanoate
CN1248738C (zh) * 2000-08-23 2006-04-05 阿克佐诺贝尔公司 用于人的睾酮酯制剂

Similar Documents

Publication Publication Date Title
JP2006520377A5 (enExample)
RU2007118196A (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
KR101749514B1 (ko) 비타민 d 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물
CA2867419C (en) Use of tetracycline compositions for wound treatment and skin restoration
CN1248738C (zh) 用于人的睾酮酯制剂
KR102297951B1 (ko) 포스파티딜콜린을 포함하는 분무가능한 국소용 담체 및 조성물
Meriggiola et al. Progestin-androgen combination regimens for male contraception
CA2979051C (en) Topical compositions comprising a corticosteroid
AU2010335656B2 (en) Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue
CN107847435B (zh) 用于治疗直肠的炎性变化的药物制剂
JP2538816B2 (ja) 動物用ビタミンa製剤
JP5815900B2 (ja) 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法
CA2496637C (en) Treatment of inflammatory conditions of the intestine using high density lipoprotein
Felden et al. Comparative Clinical Effects of Hydromorphone and Morphine: A Meta-Analysis
RU2642244C2 (ru) Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием